Latest news with #MINNEAPOLIS
Yahoo
2 days ago
- Business
- Yahoo
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: A replay of the webcast will be available on the Celcuity website following the live event. About Celcuity Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity's active clinical trials can be found at Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at Follow us on LinkedIn and X. View source version of release on Contacts: Celcuity Inc. Brian Sullivan, bsullivan@ Vicky Hahne, vhahne@ (763) 392-0123 ICR HealthcarePatti Bank, (415) 513-1284Sign in to access your portfolio
Associated Press
3 days ago
- Business
- Associated Press
Deluxe Acquires CheckMatch from Kinexys by J.P. Morgan to Extend Digital Lockbox Payments Capability
MINNEAPOLIS--(BUSINESS WIRE)--Aug 6, 2025-- Deluxe (NYSE: DLX), a trusted Payments and Data company, today announced it has completed the acquisition of CheckMatch from Kinexys by J.P. Morgan, the firm's industry-leading blockchain business unit. Consistent with the company's strategy, this acquisition will expand the Deluxe Payment Network (DPN) solution. CheckMatch is a service that digitizes the delivery of paper checks, enabling faster electronic conveyance, which was developed by Kinexys by J.P. Morgan. The DPN solution digitally connects physical lockboxes across the Deluxe network, which helps to more efficiently process payments made to thousands of businesses across the U.S. By adding CheckMatch to the platform, Deluxe further extends the company's Payments scale, enabling potential revenue and cost synergies. 'In alignment with our strategy to expand in Payments and Data, this acquisition marks a continued investment across our B2B payments portfolio,' said Barry McCarthy, President and CEO of Deluxe. 'By bringing together the strengths of CheckMatch and DPN, we are building the largest purpose-built digital lockbox network in the market—delivering value through scale, security, and simplicity in competition with traditional offerings.' Deluxe has already more than doubled the number of lockboxes accessible through DPN in the first half of 2025. Once integration of CheckMatch is completed—the combined platform is expected to include five of the top 10 U.S.-based lockbox providers and multiple leading disbursement partners, including financial institutions, AP automation platforms, and a major medical payments provider. 'We are thrilled to see CheckMatch become an integral part of a larger vision that embodies our shared commitment of bringing next-gen innovation to the world of finance and delivering exceptional value for our clients,' said Umar Farooq, Global Co-Head of J.P. Morgan Payments. 'We are confident that Deluxe is well-positioned to elevate CheckMatch to the next level and will ensure a seamless transition.' Check payments remain a critical component of the B2B payments ecosystem, particularly for large enterprises, financial institutions, and disbursement partners. This expanded inter-lockbox network delivers meaningful cost savings by eliminating postage, envelopes, labor, handling, and physical check costs for payors—including major bill pay platforms and financial institutions. For payees, the process remains virtually unchanged. Payments follow the same well-established lockbox protocols, but are now delivered digitally—streamlining operations without disrupting treasury workflows. By digitizing the delivery of check payments, the network simplifies reconciliation, improves reliability, and helps treasurers manage payments with greater speed and confidence. As the network scales, participants will benefit from increased efficiency and growing value through shared infrastructure and reach. A division of J.P. Morgan Payments, Kinexys by J.P. Morgan has exceeded $2 trillion in notional value 1 to date, processing on average $3 billion daily in transaction volume 2. Payment transactions on the platform have grown by 10x year-over-year 3, with clients now spanning five continents. The business is transforming how information, money and assets move around the world, helping clients harness the speed and efficiency enabled by blockchain technology. About Deluxe Deluxe, a Trusted Payments and Data Company, champions business so communities thrive. Our solutions help businesses pay, get paid, and grow. For more than 100 years, Deluxe customers have relied on our solutions and platforms at all stages of their lifecycle, from start-up to maturity. Our powerful scale supports millions of small businesses, thousands of vital financial institutions and hundreds of the world's largest consumer brands, while processing more than $2 trillion in annual payment volume. Our reach, scale and distribution channels position Deluxe to be our customers' most trusted business partner. To learn how we can help your business, visit us at 1. JPMC proprietary data 2024 2. JPMC proprietary data 2024 3. Based on Jan.-Aug. 2023 vs. 2024 YoY transaction volume attributed to growth driven by Kinexys Digital Payments. View source version on CONTACT: Brian Anderson, VP, Strategy & Investor Relations 651-447-4197 [email protected] Negrin, VP, Communications 612-669-1459 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MINNESOTA INDUSTRY KEYWORD: TECHNOLOGY PAYMENTS FINANCE FINTECH BUSINESS PROFESSIONAL SERVICES DIGITAL CASH MANAGEMENT/DIGITAL ASSETS SOFTWARE DATA MANAGEMENT SOURCE: Deluxe Copyright Business Wire 2025. PUB: 08/06/2025 09:18 AM/DISC: 08/06/2025 09:18 AM
Globe and Mail
4 days ago
- Business
- Globe and Mail
Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code
MINNEAPOLIS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming fluid management, today announced that the first patients have been successfully treated with Aquadex ® ultrafiltration therapy in a hospital-based outpatient setting. This milestone reflects a major advancement in the company's mission to improve access to fluid management and support better care across the continuum. The treatments were performed at a leading healthcare institution in the southeastern United States using the same Aquadex SmartFlow ® system and clinical protocols trusted in inpatient environments. By enabling therapy in a hospital-based outpatient setting, Nuwellis is helping to reimagine how and where patients with fluid overload can be supported—offering a potential new model for earlier, more proactive care. 'For patients struggling with fluid overload, access to consistent, effective therapy can make a life-changing difference,' said John Erb, CEO of Nuwellis. 'This milestone represents more than just a shift in setting—it reflects our vision for expanding how care is delivered and making fluid management more flexible, scalable, and patient-centered.' In addition to the clinical benefits, hospitals may also realize significant economic advantages by transitioning appropriate therapies to outpatient care. With outpatient reimbursement increasing from approximately $413 to $1,639 per treatment day, this model offers a more sustainable path forward for health systems facing pressure to reduce readmissions while managing complex patients more effectively. The hospital-based outpatient setting provides an opportunity to treat patients using existing venous access and care teams, without requiring hospitalization. This approach may offer significant advantages to patients who are repeatedly admitted due to volume challenges, while also helping healthcare systems manage resources more efficiently. Nuwellis continues to work closely with providers to support hospital-based outpatient program development, including training, protocols, and workflow integration. The company sees this as a foundational step in building sustainable access to ultrafiltration therapy—and a key part of its long-term strategy to expand the impact of Aquadex. For more information, please visit and to learn more about the Company's reimbursement for outpatient, please visit the reimbursement page. About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow ® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on LinkedIn or X, formerly Twitter. About the Aquadex SmartFlow ® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies. Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise. For further information, please contact:
Yahoo
4 days ago
- Business
- Yahoo
Vireo Growth Inc. to Release Second Quarter 2025 Results on August 13, 2025
MINNEAPOLIS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its second fiscal quarter ended June 30, 2025 on Wednesday, August 13, 2025 before the market opens. Vireo Growth management will host a conference call with the investment community that same day, Wednesday, August 13, 2025 at 8:30 a.m. ET (7:30 a.m. CT) to discuss its results. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174. A live audio webcast of this event will also be available in the Events & Presentations section of the Company's Investor Relations website and via the following link: About Vireo Growth Inc. Vireo was founded in 2014 as a medical cannabis pioneer—and we've never stopped pushing boundaries. We're building the most disciplined, strategically aligned, and execution-focused platform in the industry. That means staying relentlessly local while leveraging the strength of a national portfolio, backing exceptional leaders, and deploying capital and talent where it drives the most value. Vireo operates with a long-term mindset, a bias for action, and an unapologetic commitment to its customers, employees, shareholders, industry collaborators, and the communities it calls home. For more information about Vireo, visit Contact Information Joe DuxburyChief Accounting Officerinvestor@ 314-8995
Yahoo
5 days ago
- Business
- Yahoo
Centerspace Reports Second Quarter 2025 Financial & Operating Results and Updates 2025 Financial Outlook
MINNEAPOLIS, Aug. 4, 2025 /PRNewswire/ -- Centerspace (NYSE: CSR) announced today its financial and operating results for the three and six months ended June 30, 2025. The tables below show Net Loss, Funds from Operations ("FFO")1, and Core FFO1, all on a per diluted share basis, for the three and six months ended June 30, 2025; Same-Store Revenues, Expenses, and Net Operating Income ("NOI")1 over comparable periods; and Same-Store Weighted Average Occupancy, Lease Rate Growth, and Resident Retention for each of the three months ended June 30, 2025, March 31, 2025, and June 30, 2024 and the six months ended June 30, 2025 and 2024. Three Months Ended June 30,Six Months Ended June 30, Per Common Share2025202420252024 Net loss - diluted$ (0.87)$ (0.19)$ (1.09)$ (0.56) FFO - diluted(1)$ 1.24$ 1.23$ 2.42$ 2.39 Core FFO - diluted(1)$ 1.28$ 1.27$ 2.50$ 2.49 Year-Over-Year ComparisonSequential Comparison Same-Store Results(2)Q2 2025 vs. Q2 2024Q2 2025 vs. Q1 2025 Revenues2.7 %1.1 % Expenses2.4 %(1.3) % Net Operating Income ("NOI")(1)2.9 %2.6 % Three months endedSix months ended Same-Store Results(2)June 30, 2025March 31, 2025June 30, 2024June 30, 2025June 30, 2024 Weighted Average Occupancy96.1 %95.9 %95.5 %96.0 %95.1 % New Lease Rate Growth2.1 %(1.2) %3.2 %0.6 %1.9 % Renewal Lease Rate Growth2.6 %3.4 %3.5 %2.8 %3.5 % Blended Lease Rate Growth (3)2.4 %0.6 %3.4 %1.8 %2.7 % Retention Rate60.2 %49.2 %59.1 %56.8 %58.5 % (1) NOI, FFO, and Core FFO are non-GAAP financial measures. For more information on their usage and presentation, and a reconciliation to the most directly comparable GAAP measures, refer to "Non-GAAP Financial Measures and Reconciliations" and "Non-GAAP Financial Measures and Other Terms" in the Supplemental Financial and Operating Data below. (2) Same-store results are updated for annual composition change including acquisition, disposition, changes in held for sale classification, and repositioning activity. Refer to "Non-GAAP Financial Measures and Reconciliations" in Supplemental and Financial Operating Data within. (3) Blended lease rate growth is weighted by lease count. Overview of the Second Quarter Acquired Sugarmont, the Company's first apartment community in Salt Lake City, Utah, consisting of 341 homes for an aggregate purchase price of $149.0 million; Revenue for the second quarter of 2025 increased by $3.5 million or 5.4% to $68.5 million, compared to $65.0 million for the second quarter of 2024; Same-store revenues increased by 2.7% for the second quarter of 2025 compared to the second quarter of 2024, driving a 2.9% increase in same-store NOI compared to the same period of the prior year; Net loss was $0.87 per diluted share for the second quarter of 2025, compared to net loss of $0.19 per diluted share for the same period of the prior year; and Core FFO per diluted share increased 0.8% to $1.28 for the three months ended June 30, 2025, compared to $1.27 for the three months ended June 30, 2024. Balance Sheet At the end of the second quarter, Centerspace had $206.3 million of total liquidity on its balance sheet, consisting of $194.0 million available under the lines of credit and cash and cash equivalents of $12.4 million. Updated 2025 Financial Outlook Centerspace updated its 2025 financial outlook. For additional information, see S-17 of the Supplemental Financial and Operating Data for the quarter ended June 30, 2025 included at the end of this release. These ranges should be considered in their entirety. The table below reflects the updated Outlook for 2025 Updated Outlook for 2025Low High Low High Net loss per Share – diluted $(0.71) $(0.45) $2.50 $2.76 Same-Store Revenue 1.50 % 3.50 % 2.00 % 3.00 % Same-Store Expenses 2.00 % 4.00 % 1.00 % 2.50 % Same-Store NOI 1.25 % 3.25 % 2.50 % 3.50 % FFO per Share – diluted $4.73 $4.97 $4.70 $4.83 Core FFO per Share – diluted $4.86 $5.10 $4.88 $5.00 Additional assumptions: Same-store recurring capital expenditures of $1,150 per home to $1,200 per home Value-add expenditures of $16.0 million to $18.0 million Proceeds from dispositions of $210.0 million to $230.0 million Note: FFO, Core FFO. and NOI are non-GAAP financial measures. For more information on their usage and presentation and a reconciliation to the most comparable GAAP measure, please refer to "2025 Financial Outlook" in the Supplemental Financial and Operating Data within. Subsequent Events On July 29, 2025, Centerspace closed on the acquisition of Railway Flats a 420 home apartment community located in Loveland, CO, for $132.2 million which includes the assumption of $76.5 million mortgage debt. Earnings Call Live webcast and replay: Conference CallConference Call Replay Tuesday, August 5, 2025, at 10:00 AM ETReplay available until August 12, 2025 USA Toll Free 1-833-470-1428USA Toll Free 1-866-813-9403 International 1-404-975-4839International 1-929-458-6194 Canada Toll Free 1-833-950-0062Access Code 547256Access Code 134183 Supplemental Information Supplemental Operating and Financial Data for the quarter ended June 30, 2025 included herein ("Supplemental Information"), is available in the Investors section on Centerspace's website at or by calling Investor Relations at 952-401-6600. Non-GAAP financial measures and other capitalized terms, as used in this earnings release, are defined and reconciled in the Supplemental Financial and Operating Data, which accompanies this earnings release. About Centerspace Centerspace is an owner and operator of apartment communities committed to providing great homes by focusing on integrity and serving others. Founded in 1970, as of June 30, 2025, Centerspace owned 72 apartment communities consisting of 13,353 apartment homes located in Colorado, Minnesota, Montana, Nebraska, North Dakota, South Dakota, and Utah. Centerspace was named a top workplace for the sixth consecutive year in 2025 by the Minneapolis Star Tribune. For more information, please visit Forward-Looking Statements Certain statements in this press release and the Supplemental Operating and Financial Data are based on the Company's current expectations and assumptions, and are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements do not discuss historical fact, but instead include statements related to expectations, projections, intentions or other items related to the future. Forward-looking statements are typically identified by the use of terms such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," "assumes," "may," "projects," "outlook," "future," and variations of such words and similar expressions. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from the results of operations, financial conditions, or plans expressed or implied by the forward-looking statements. Although the Company believes the expectations reflected in its forward-looking statements are based upon reasonable assumptions, it can give no assurance that the expectations will be achieved. Any statements contained herein that are not statements of historical fact should be deemed forward-looking statements. As a result, reliance should not be placed on these forward-looking statements, as these statements are subject to known and unknown risks, uncertainties, and other factors beyond the Company's control and could differ materially from actual results and performance. Such risks and uncertainties are detailed from time to time in filings with the Securities and Exchange Commission ("SEC"), including the "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, in its subsequent quarterly reports on Form 10-Q, and in other reports the Company files with the SEC from time to time. The Company assumes no obligation to update or supplement forward-looking statements that become untrue due to subsequent events. Contact Information Investor RelationsJosh KlaetschPhone: 952-401-6600Email: IR@ Marketing & MediaKelly WeberPhone: 952-401-6600Email: kweber@ View original content to download multimedia: SOURCE Centerspace
